Covered recipient · General Payments record
JENNIFER TORO GALARZA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,587.25
- Reported across 152 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $332.16 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $176.58 | 7 |
| Lilly USA, LLC | $46.77 | 3 |
| Novo Nordisk AS | $35.45 | 2 |
| PFIZER INC. | $21.03 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.40 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.87 | 1 |
| GlaxoSmithKline, LLC. | $14.06 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $31.27 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233178 | CMS |
| ABBVIE INC. | $31.15 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233180 | CMS |
| ABBVIE INC. | $20.42 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233182 | CMS |
| ABBVIE INC. | $10.82 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233184 | CMS |
| ABBVIE INC. | $34.67 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233186 | CMS |
| ABBVIE INC. | $34.19 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233188 | CMS |
| ABBVIE INC. | $14.06 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106233190 | CMS |
| GlaxoSmithKline, LLC. | $14.06 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116088981 | CMS |
| Lilly USA, LLC | $14.80 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135063275 | CMS |
| Lilly USA, LLC | $17.55 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135063277 | CMS |
| Lilly USA, LLC | $14.42 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135044634 | CMS |
| Novartis Pharmaceuticals Corporation | $18.87 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087356584 | CMS |
| Novo Nordisk Inc | $14.05 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096924540 | CMS |
| Novo Nordisk Inc | $21.40 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096792568 | CMS |
| PFIZER INC. | $21.03 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131985171 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.40 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153524065 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.